Cargando…

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy

CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy can play an important role in combined modali...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Penny Q., Gunther, Jillian R., Wu, Susan Y., Dabaja, Bouthaina S., Nastoupil, Loretta J., Ahmed, Sairah, Neelapu, Sattva S., Pinnix, Chelsea C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027336/
https://www.ncbi.nlm.nih.gov/pubmed/33842363
http://dx.doi.org/10.3389/fonc.2021.648655
_version_ 1783675796724908032
author Fang, Penny Q.
Gunther, Jillian R.
Wu, Susan Y.
Dabaja, Bouthaina S.
Nastoupil, Loretta J.
Ahmed, Sairah
Neelapu, Sattva S.
Pinnix, Chelsea C.
author_facet Fang, Penny Q.
Gunther, Jillian R.
Wu, Susan Y.
Dabaja, Bouthaina S.
Nastoupil, Loretta J.
Ahmed, Sairah
Neelapu, Sattva S.
Pinnix, Chelsea C.
author_sort Fang, Penny Q.
collection PubMed
description CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy can play an important role in combined modality treatments for some patients undergoing CAR T-cell therapy in various clinical settings. In this review, we discuss the current evidence for RT in the setting of CAR T-cell therapy for patients with hematologic malignancies and propose potential opportunities for future investigation of RT and CAR T-cell treatment synergy. Future research frontiers include investigation of hypotheses including radiation priming of CAR T-cell mediated death, pre-CAR T-cell tumor debulking with radiation therapy, and selection of high risk patients for early radiation salvage after CAR T cell therapy.
format Online
Article
Text
id pubmed-8027336
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80273362021-04-09 Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy Fang, Penny Q. Gunther, Jillian R. Wu, Susan Y. Dabaja, Bouthaina S. Nastoupil, Loretta J. Ahmed, Sairah Neelapu, Sattva S. Pinnix, Chelsea C. Front Oncol Oncology CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy can play an important role in combined modality treatments for some patients undergoing CAR T-cell therapy in various clinical settings. In this review, we discuss the current evidence for RT in the setting of CAR T-cell therapy for patients with hematologic malignancies and propose potential opportunities for future investigation of RT and CAR T-cell treatment synergy. Future research frontiers include investigation of hypotheses including radiation priming of CAR T-cell mediated death, pre-CAR T-cell tumor debulking with radiation therapy, and selection of high risk patients for early radiation salvage after CAR T cell therapy. Frontiers Media S.A. 2021-03-25 /pmc/articles/PMC8027336/ /pubmed/33842363 http://dx.doi.org/10.3389/fonc.2021.648655 Text en Copyright © 2021 Fang, Gunther, Wu, Dabaja, Nastoupil, Ahmed, Neelapu and Pinnix. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Fang, Penny Q.
Gunther, Jillian R.
Wu, Susan Y.
Dabaja, Bouthaina S.
Nastoupil, Loretta J.
Ahmed, Sairah
Neelapu, Sattva S.
Pinnix, Chelsea C.
Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title_full Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title_fullStr Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title_full_unstemmed Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title_short Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
title_sort radiation and car t-cell therapy in lymphoma: future frontiers and potential opportunities for synergy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027336/
https://www.ncbi.nlm.nih.gov/pubmed/33842363
http://dx.doi.org/10.3389/fonc.2021.648655
work_keys_str_mv AT fangpennyq radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT guntherjillianr radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT wususany radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT dabajabouthainas radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT nastoupillorettaj radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT ahmedsairah radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT neelapusattvas radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy
AT pinnixchelseac radiationandcartcelltherapyinlymphomafuturefrontiersandpotentialopportunitiesforsynergy